C. David Marsden

Neurology King's College (London), London, England, United Kingdom 
"C. Marsden"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rinne UK, Bracco F, Chouza C, et al. (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55: 23-30
Rinne UK, Bracco F, Chouza C, et al. (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 48: 363-8
Smith L, De Salvia M, Jenner P, et al. (1996) An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 125-35
Gnanalingham KK, Jenner P, Hunter AJ, et al. (1995) The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology. 117: 287-297
Burn DJ, Mark MH, Playford ED, et al. (1992) Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 42: 1894-900
Lange KW, Löschmann PA, Wachtel H, et al. (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. European Journal of Pharmacology. 212: 247-52
Rose S, Nomoto M, Jenner P, et al. (1990) Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochemical Pharmacology. 38: 3677-81
Temlett JA, Chong PN, Oertel WH, et al. (1989) The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. European Journal of Pharmacology. 156: 197-206
Temlett JA, Quinn NP, Jenner PG, et al. (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 261-5
Rose S, Nomoto M, Kelly E, et al. (1989) Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neuroscience Letters. 101: 305-310
See more...